Toll-like receptor 8 agonists - Pipeline Insight, 2022

“Toll-Like Receptor 7, 8 (TLR-8) Agonist - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Toll-Like Receptor 7, 8 (TLR-8) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Toll-Like Receptor 7, 8 (TLR-8) Agonist Understanding

Toll-Like Receptor 7, 8 (TLR-8) Agonist: Overview

Toll-like receptors (TLR) sense distinct pathogen associated molecular patterns (PAMPs) and initiate inflammatory reactions important for innate and adaptive defense. The extracellular domains of TLRs contain 20e26 LRR modules and form a horseshoe-shaped right-handed curved solenoid that is characteristic of LRR proteins. Human TLR8 is highly expressed as a functional cleavage product in endosomes of monocytes and macrophages. TLR8 are receptors for single-stranded RNA that reside in the endosome. Toll-like receptors 8 (TLR8) is broadly expressed on antigen-presenting cells, making TLR8 agonists likely candidates for the development of new vaccine adjuvants. The potential role of TLR8 in the generation of a critical immune response against bacterial infection and cancer is an area of investigation.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Toll-Like Receptor 7, 8 (TLR-8) Agonist R&D. The therapies under development are focused on novel approaches for Toll-Like Receptor 7, 8 (TLR-8) Agonist.

Toll-Like Receptor 7, 8 (TLR-8) Agonist Emerging Drugs Chapters

This segment of the Toll-Like Receptor 7, 8 (TLR-8) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Toll-Like Receptor 7, 8 (TLR-8) Agonist Emerging Drugs
• UGN-201: UroGen Pharma

UGN-201 is a novel, liquid formulation of imiquimod, a toll-like receptor 7/8 (TLR7/8) agonist, which is known to elicit an immune response to bladder cancer. This investigational local immunotherapy is in Phase I clinical studies for the treatment of high-grade NMIBC. The FDA has granted Orphan Drug Designation to UGN-201 for the treatment of carcinoma in situ (CIS).
• SBT6050: Silverback Therapeutics

SBT6050 is a therapeutic comprised of a potent toll-like receptor 8 (TLR8) agonist conjugated to a HER2 directed monoclonal antibody. The drug is delivered systemically with tumor localized activation of myeloid cells. The drug is in Phase I clinical studies for the treatment of HER2 positive solid tumors.

Further product details are provided in the report……..

Toll-Like Receptor 7, 8 (TLR-8) Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Toll-Like Receptor 7, 8 (TLR-8) Agonist drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Toll-Like Receptor 7, 8 (TLR-8) Agonist

There are approx. 10+ key companies which are developing the Toll-Like Receptor 7, 8 (TLR-8) Agonist. The companies which have their Toll-Like Receptor 7, 8 (TLR-8) Agonist drug candidates in the most advanced stage, i.e. Phase I include, UroGen Pharma.
• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Toll-Like Receptor 7, 8 (TLR-8) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Toll-Like Receptor 7, 8 (TLR-8) Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Toll-Like Receptor 7, 8 (TLR-8) Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Toll-Like Receptor 7, 8 (TLR-8) Agonist drugs.

Toll-Like Receptor 7, 8 (TLR-8) Agonist Report Insights
• Toll-Like Receptor 7, 8 (TLR-8) Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Toll-Like Receptor 7, 8 (TLR-8) Agonist Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Toll-Like Receptor 7, 8 (TLR-8) Agonist drugs?
• How many Toll-Like Receptor 7, 8 (TLR-8) Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Toll-Like Receptor 7, 8 (TLR-8) Agonist?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Toll-Like Receptor 7, 8 (TLR-8) Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Toll-Like Receptor 7, 8 (TLR-8) Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• UroGen Pharma
• Silverback Therapeutics
• Seven and Eight Biopharmaceuticals
• Nektar Therapeutics
• Ascendis Pharma
• CureVac
• Cello Therapeutics
• Zhimeng Biopharma

Key Products
• UGN-201
• SBT6050
• SBT6290
• SBT8230
• BDB-001
• NKTR-262
• TransCon TLR 7/8 agonist
• CV8102
• CE-120
• Research programme : toll-like receptor 8 agonist